Cybin Inc. CYBN Archives - Page 9 of 18

MondayMar 21, 2022 2:09 pm

QualityStocksNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Planning Pilot Study of CYB004, Pursuing Multiple Opportunities to Secure, Support Patent Position for R&D

Cybin (NYSE American: CYBN) (NEO: CYBN), a leading ethical biopharmaceutical company working to advance psychedelic therapeutics for various psychiatric and neurological conditions, recently received its first official issued patent. The U.S. Patent and Trademark Office (“USPTO”) has granted patent 11,242,318 to Cybin’s proprietary CYB004, the company’s lead investigational proprietary DMT compound. According to Cybin CEO Doug Drysdale, the patent adds strong protection to the company’s growing intellectual property portfolio of psychedelic-based compounds, supporting and protecting the investments it is making in its CYB004 program. “Under the patent, allowed claims include a range of deuterated forms of DMT and 5-MeO-DMT; the…

ThursdayMar 17, 2022 9:00 am

Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) on Leading Edge of Development of Psychedelics as Public Support Grows

More than 60% of American who suffer from mental health conditions want access to psychedelic options Growing number of cities, states looking at decriminalizing use of psychedelic medicine Cybin is working with world-class partners, internationally recognized scientists to create safe, effective therapeutics in the mental-health space The awareness of psychedelics and the potential for treating an array of mental health diseases is growing, as evidenced by a recent survey reporting that 65% of affected Americans want access to psychedelics for potential treatment (https://ibn.fm/jIV2K). Those are numbers that Cybin (NEO: CYBN) (NYSE American: CYBN), a leading ethical biopharmaceutical company, is paying close attention…

WednesdayMar 16, 2022 11:21 am

QualityStocksNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Announces Participation in Upcoming Maxim Group Virtual Growth Conference

Cybin (NEO: CYBN) (NYSE American: CYBN), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics(TM) is planning to participate in the 2022 Virtual Growth Conference. The conference is slated for March 28–30, 2022, from 9 a.m. to 5 p.m. ET. Cybin CEO Doug Drysdale will present at the premier event, which is presented by Maxim Group LLC and hosted by M-Vest. Drysdale’s presentation will be available on demand at 9 a.m. ET on Monday, March 28. An archived version of Drysdale’s webcast will be available on the Company’s investor relations website. To view Drysdale’s presentation, visit https://ibn.fm/b928V To view the full press…

WednesdayMar 09, 2022 1:50 pm

QualityStocksNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Eyes Potential of First-of-Its-Kind Study

Cybin (NYSE American: CYBN) (NEO: CYBN), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics(TM), recently secured approval to move forward on a key feasibility study designed to measure ketamine’s psychedelic effect on cerebral cortex hemodynamics. The Institution Review Board (“IRB”) granted the approval, which gives a green light to a Cybin-sponsored study designed around Kernel’s quantitative neuroimaging technology, Kernel Flow. The technology uses pulsed light instead of continuous wave light to increase measured brain information. The Flow device is a wearable helmet, in contrast to electroencephalography (“EEG”) electrodes that usually require the application of gel or functional magnetic resonance…

MondayMar 07, 2022 11:00 am

Cybin Inc. (NEO: CYBN) (NYSE American: CYBN), Chopra Foundation Partner in Efforts to Support Progress Toward Psychedelic-Based Therapeutics

Psychedelic drugs are on cusp of entering mainstream treatment for mental illness Cybin, Chopra Foundation to collaborate on efforts aimed to support education, awareness about psychedelic therapy mental health research Cybin “one of the only companies that may truly address the needs of patients and providers,” says Dr. Deepak Chopra A significant increase in research and growing public support are key indicators of the future of psychedelics, which are “on the cusp of entering mainstream psychiatry,” according to a recent “New York Times” article (https://ibn.fm/GshwS). Another strong indicator of the future of psychedelics is the exciting partnership just announced by…

ThursdayMar 03, 2022 9:00 am

Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Granted U.S. Patent for Deuterated DMT

Company announced the first officially issued patent Patent provides strong protection for Cybin’s growing IP portfolio of psychedelic-based compounds CYB004 has demonstrated potential efficacy at lower doses while increasing duration of drug effect that may alleviate common negative experiences In a milestone moment for psychedelic therapeutics company Cybin (NEO: CYBN) (NYSE American: CYBN), the company has announced its first official issued patent. The U.S. Patent and Trademark Office (“USPTO”) has granted U.S. patent 11,242,318 to Cybin’s proprietary CYB004, the company’s lead investigational proprietary DMT compound. “From the outset, Cybin has focused on creating differentiated compounds that harness the potential efficacy of…

WednesdayMar 02, 2022 11:07 am

QualityStocksNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) CEO to Participate in Fireside Chat at Oppenheimer Annual Healthcare Conference

Cybin (NYSE American: CYBN) (NEO: CYBN), a biopharmaceutical company focused on progressing “Psychedelics to Therapeutics(TM),” has announced that its Chief Executive Officer Doug Drysdale will participate in a fireside chat at the Oppenheimer 32nd Annual Healthcare Conference. Drysdale’s presentation is slated to begin at 8:40 a.m. ET on Wednesday, March 16, 2022. Interested parties should visit https://ibn.fm/4Yog7 to register for the event and access the webcast. An archived version of the webcast will be available on the company’s investor relations website. To view the full press release, visit https://ibn.fm/ZFSyI About Cybin Inc. Cybin is a leading ethical biopharmaceutical company working…

FridayFeb 25, 2022 1:10 pm

QualityStocksNewsBreaks – Cybin Inc.’s (NYSE American: CYBN) (NEO: CYBN) Feasibility Study to Potentially Open New Frontiers of Understanding Psychedelics

Cybin (NYSE American: CYBN) (NEO: CYBN), a leading ethical biopharmaceutical company working to advance psychedelic therapeutics for various psychiatric and neurological conditions, recently announced its receipt of approval from an Institutional Review Board (“IRB”) for a feasibility study using Kernel’s quantitative neuroimaging technology, Kernel Flow. Enrollment for the study is set to begin early this year. The feasibility study is designed to utilize Kernel’s Flow technology to evaluate ketamine’s psychedelic effect on the cerebral cortex, potentially providing crucial information that may lead to new frontiers in psychedelic therapeutics by enabling the acquisition of longitudinal brain activity before, during and after…

FridayFeb 18, 2022 11:22 am

QualityStocksNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Reports Achievement of Additional Adelia Milestone

Cybin (NEO: CYBN) (NYSE American: CYBN),a biopharmaceutical company focused has announced that subsidiary Adelia Therapeutics Inc. has achieved a milestone outlined in the contribution agreement between Cybin, Cybin Corp., Cybin US Holdings Inc. and previous Adelia shareholders; the milestone was identified as Year 2 Q2 (iii). According to the transaction agreement, 17,239.5 Cybin class B common shares will be issued to Adelia shareholders when relevant milestones have been met; the class B Shares will be exchangeable for common shares in the capital of Cybin at an exchange rate of 10 to 1. Adelia is working on developing medicinal psychedelics with improved…

WednesdayFeb 16, 2022 11:35 am

QualityStocksNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) CEO to Participate in Fireside Chat at Aegis Virtual Conference

Cybin (NYSE American: CYBN) (NEO: CYBN), a biopharmaceutical company focused on progressing “Psychedelics to Therapeutics(TM),” today announced that its CEO Doug Drysdale will participate in a fireside chat at the Aegis Virtual Conference. The event will span three days, from Feb 23-25, 2022, with Drysdale’s presentation scheduled to begin at 2 p.m. ET on Thursday, Feb. 24. Interested parties should visit https://ibn.fm/eqPBg to listen to the event and access the webcast. An archived webcast will also be available on the company’s investor relations website. To view the full press release, visit https://ibn.fm/qjBqv About Cybin Inc. Cybin is a leading ethical…

Site Search

Company Search

Tag: Cybin Inc. CYBN